Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.35
ACT's Cash to Debt is ranked higher than
55% of the 812 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. ACT: 0.35 )
ACT' s 10-Year Cash to Debt Range
Min: 0.04   Max: 43.62
Current: 0.35

0.04
43.62
Equity to Asset 0.38
ACT's Equity to Asset is ranked higher than
53% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. ACT: 0.38 )
ACT' s 10-Year Equity to Asset Range
Min: 0.25   Max: 0.93
Current: 0.38

0.25
0.93
F-Score: 7
Z-Score: 3.12
M-Score: -2.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 4.89
ACT's Operating margin (%) is ranked higher than
67% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.15 vs. ACT: 4.89 )
ACT' s 10-Year Operating margin (%) Range
Min: -21.33   Max: 37.1
Current: 4.89

-21.33
37.1
Net-margin (%) 0.62
ACT's Net-margin (%) is ranked higher than
60% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.37 vs. ACT: 0.62 )
ACT' s 10-Year Net-margin (%) Range
Min: -22.48   Max: 35.15
Current: 0.62

-22.48
35.15
ROE (%) 0.86
ACT's ROE (%) is ranked higher than
61% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.47 vs. ACT: 0.86 )
ACT' s 10-Year ROE (%) Range
Min: -23.54   Max: 24.1
Current: 0.86

-23.54
24.1
ROA (%) 0.32
ACT's ROA (%) is ranked higher than
61% of the 816 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.07 vs. ACT: 0.32 )
ACT' s 10-Year ROA (%) Range
Min: -13.02   Max: 21.31
Current: 0.32

-13.02
21.31
ROC (Joel Greenblatt) (%) 16.79
ACT's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 812 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.76 vs. ACT: 16.79 )
ACT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -39.46   Max: 93.56
Current: 16.79

-39.46
93.56
Revenue Growth (%) 28.50
ACT's Revenue Growth (%) is ranked higher than
91% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.90 vs. ACT: 28.50 )
ACT' s 10-Year Revenue Growth (%) Range
Min: 6.4   Max: 40.5
Current: 28.5

6.4
40.5
EBITDA Growth (%) -2.90
ACT's EBITDA Growth (%) is ranked higher than
64% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. ACT: -2.90 )
ACT' s 10-Year EBITDA Growth (%) Range
Min: -4.4   Max: 52.9
Current: -2.9

-4.4
52.9
» ACT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ACT Guru Trades in Q4 2013

Diamond Hill Capital 93,086 sh (New)
Jim Simons 197,625 sh (New)
George Soros 25,000 sh (New)
John Griffin 1,310,000 sh (New)
Jeremy Grantham 18,296 sh (New)
Private Capital 172,950 sh (New)
RS Investment Management 1,058,482 sh (+485.33%)
Steven Cohen 56,514 sh (+31.62%)
Paul Tudor Jones 1,700 sh (+21.43%)
Daniel Loeb 15,000 sh (unchged)
Vanguard Health Care Fund 986,000 sh (unchged)
Eric Mindich 500,000 sh (unchged)
Mario Gabelli 39,371 sh (-0.73%)
Pioneer Investments 806,036 sh (-3.96%)
Andreas Halvorsen 2,931,923 sh (-9.76%)
Scott Black 81,068 sh (-10.08%)
Francis Chou 35,400 sh (-53.85%)
» More
Q1 2014

ACT Guru Trades in Q1 2014

Leon Cooperman 264,093 sh (New)
Daniel Loeb 2,500,000 sh (New)
John Paulson 300,000 sh (New)
Louis Moore Bacon 5,003 sh (New)
Joel Greenblatt 10,597 sh (New)
Ken Heebner 630,000 sh (New)
Steve Mandel 2,378,308 sh (New)
Paul Tudor Jones 53,200 sh (+3029.41%)
Vanguard Health Care Fund 3,647,500 sh (+269.93%)
Jim Simons 401,936 sh (+103.38%)
Steven Cohen 83,190 sh (+47.2%)
George Soros 35,000 sh (+40%)
John Griffin 1,735,000 sh (+32.44%)
Private Capital 174,960 sh (+1.16%)
Francis Chou 35,400 sh (unchged)
Eric Mindich 500,000 sh (unchged)
RS Investment Management 939,682 sh (-11.22%)
Scott Black 67,883 sh (-16.26%)
Mario Gabelli 31,363 sh (-20.34%)
Pioneer Investments 620,874 sh (-22.97%)
Andreas Halvorsen 1,091,544 sh (-62.77%)
Diamond Hill Capital 18,613 sh (-80%)
Jeremy Grantham 1,306 sh (-92.86%)
Bill Nygren -693,000 sh (-9999%)
» More
Q2 2014

ACT Guru Trades in Q2 2014

Jean-Marie Eveillard 706,833 sh (New)
Kyle Bass 14,800 sh (New)
Bill Nygren 0 sh (+9999%)
Louis Moore Bacon 47,348 sh (+846.39%)
Leon Cooperman 619,919 sh (+134.74%)
Paul Tudor Jones 101,500 sh (+90.79%)
George Soros 63,831 sh (+82.37%)
Eric Mindich 692,000 sh (+38.4%)
Jim Simons 507,725 sh (+26.32%)
Mario Gabelli 36,165 sh (+15.31%)
Andreas Halvorsen 1,207,824 sh (+10.65%)
Steve Mandel 2,478,628 sh (+4.22%)
Steven Cohen 25,000 sh (unchged)
Daniel Loeb 2,500,000 sh (unchged)
John Paulson 300,000 sh (unchged)
John Griffin 1,735,000 sh (unchged)
Francis Chou Sold Out
Joel Greenblatt Sold Out
Jeremy Grantham Sold Out
Diamond Hill Capital Sold Out
Private Capital 172,284 sh (-1.53%)
Vanguard Health Care Fund 3,359,667 sh (-7.89%)
RS Investment Management 845,397 sh (-10.03%)
Scott Black 48,858 sh (-28.03%)
Ken Heebner 370,000 sh (-41.27%)
Pioneer Investments 256,641 sh (-58.66%)
» More
Q3 2014

ACT Guru Trades in Q3 2014

Vanguard Health Care Fund 8,555,596 sh (+154.66%)
» More
» Details

Insider Trades

Latest Guru Trades with ACT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-09-30 Add 154.66%3.22%$202.72 - $248 $ 243.219%8555596
Ken Heebner 2014-06-30 Reduce -41.27%1.44%$188.83 - $224.21 $ 243.2118%370000
Bill Nygren 2014-06-30 Buy to Cover1.1%$188.83 - $224.21 $ 243.2118%0
Leon Cooperman 2014-06-30 Add 134.74%1.03%$188.83 - $224.21 $ 243.2118%619919
Scott Black 2014-06-30 Reduce -28.03%0.42%$188.83 - $224.21 $ 243.2118%48858
Jean-Marie Eveillard 2014-06-30 New Buy0.38%$188.83 - $224.21 $ 243.2118%706833
Vanguard Health Care Fund 2014-06-30 Reduce -7.89%0.17%$188.83 - $224.21 $ 243.2118%3359667
Andreas Halvorsen 2014-06-30 Add 10.65%0.12%$188.83 - $224.21 $ 243.2118%1207824
George Soros 2014-06-30 Add 82.37%0.05%$188.83 - $224.21 $ 243.2118%63831
Joel Greenblatt 2014-06-30 Sold Out 0.03%$188.83 - $224.21 $ 243.2118%0
Daniel Loeb 2014-03-31 New Buy7.6%$165.64 - $227.26 $ 243.2124%2500000
Ken Heebner 2014-03-31 New Buy3.5%$165.64 - $227.26 $ 243.2124%630000
Steve Mandel 2014-03-31 New Buy2.1%$165.64 - $227.26 $ 243.2124%2378308
Vanguard Health Care Fund 2014-03-31 Add 269.93%1.53%$165.64 - $227.26 $ 243.2124%3647500
Andreas Halvorsen 2014-03-31 Reduce -62.77%1.44%$165.64 - $227.26 $ 243.2124%1091544
Bill Nygren 2014-03-31 Sell short-1.1%$165.64 - $227.26 $ 243.2124%-693000
John Griffin 2014-03-31 Add 32.44%0.96%$165.64 - $227.26 $ 243.2124%1735000
Leon Cooperman 2014-03-31 New Buy0.72%$165.64 - $227.26 $ 243.2124%264093
John Paulson 2014-03-31 New Buy0.3%$165.64 - $227.26 $ 243.2124%300000
Scott Black 2014-03-31 Reduce -16.26%0.24%$165.64 - $227.26 $ 243.2124%67883
Joel Greenblatt 2014-03-31 New Buy0.03%$165.64 - $227.26 $ 243.2124%10597
George Soros 2014-03-31 Add 40%0.02%$165.64 - $227.26 $ 243.2124%35000
Mario Gabelli 2014-03-31 Reduce -20.34%0.01%$165.64 - $227.26 $ 243.2124%31363
Private Capital 2013-12-31 New Buy3.6%$137.3 - $166.73 $ 243.2156%172950
John Griffin 2013-12-31 New Buy2.3%$137.3 - $166.73 $ 243.2156%1310000
Andreas Halvorsen 2013-12-31 Reduce -9.76%0.25%$137.3 - $166.73 $ 243.2156%2931923
Scott Black 2013-12-31 Reduce -10.08%0.15%$137.3 - $166.73 $ 243.2156%81068
George Soros 2013-12-31 New Buy0.04%$137.3 - $166.73 $ 243.2156%25000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Actavis PLC

Bernard Horn Comments on Actavis PLC - Oct 30, 2014

On July 1, Actavis (ACT) announced the completion of its acquisition of Forest Laboratories Inc. (a Fund holding), in a cash and equity transaction valued at approximately $28 billion. We maintained a position in Actavis, as its pro-forma financial statements fit the Polaris valuation profile. As one of the largest generic pharmaceutical companies, Actavis is expected to broaden its product platform with the Forest acquisition, increase operating cash flow and realize $1 billion in cost synergies.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Q3 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Diamond Hill Capital Comments on Actavis PLC - Jul 25, 2014

We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott.

From Diamond Hill Capital (Trades, Portfolio)'s Small Cap Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Actavis Inc - Jun 26, 2014

Pharmaceutical company Actavis, Inc. PLC (ACT) announced the acquisition of drug manufacturer Forest Laboratories, Inc. during the quarter for a combination of cash and stock. Investors viewed this as a positive for Actavis due to expected synergies and an increase in the branded drug business as a percent of revenues.



From Diamond Hill Capital's Small Cap Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Francis Chou Comments on Actavis Inc. - Sep 05, 2013

Another big winner was Actavis Inc. (ACT), formerly Watson Pharmaceutical. We first purchased Actavis in 2006 at $25. We kept buying the shares in 2007, and on June 30, 2013, it was priced at $126.22. It shows that when you are accurate in your estimation of intrinsic value and buy them at a significant discount, add in good management and respectable growth in intrinsic value, the investment works out really well. This is true even if you bought them when the market indices were trading at an all-time high. "Value traps" generally occur when you are wrong in your estimation of intrinsic value, pay too much and the company's intrinsic value is static and/or decreasing in value.

From Francis Chou's semi-annual report 2013.

Check out Francis Chou latest stock trades

Top Ranked Articles about Actavis PLC

Bernard Horn Comments on Actavis PLC
On July 1, Actavis (ACT) announced the completion of its acquisition of Forest Laboratories Inc. (a Fund holding), in a cash and equity transaction valued at approximately $28 billion. We maintained a position in Actavis, as its pro-forma financial statements fit the Polaris valuation profile. As one of the largest generic pharmaceutical companies, Actavis is expected to broaden its product platform with the Forest acquisition, increase operating cash flow and realize $1 billion in cost synergies. Read more...
Diamond Hill Capital Comments on Actavis PLC
We eliminated our position in specialty pharmaceutical company Actavis PLC (ACT) as the price to intrinsic value relationship narrowed. We originally received shares when Actavis bought portfolio holding Warner Chilcott. Read more...
Diamond Hill Capital Comments on Actavis Inc
Pharmaceutical company Actavis, Inc. PLC (ACT) announced the acquisition of drug manufacturer Forest Laboratories, Inc. during the quarter for a combination of cash and stock. Investors viewed this as a positive for Actavis due to expected synergies and an increase in the branded drug business as a percent of revenues. Read more...
Top 5 Hedge Fund Net Buys
The recent top net buys of the hedge fund gurus were American Airlines (AAL), Actavis (ACT), Allegion (ALLE), Gilead Sciences (GILD), and Verizon (VZ). I found the net buys by using the S&P 500 Grid at GuruFocus. I adjusted the setting to include only hedge fund gurus and examined the results for both S&P 500 companies and non-S&P 500 companies. Read more...
Weekly 52-Week Highs Highlight: ACT, NVO, NXPI, WYNN
According to GuruFocus list of 52-week highs; Actavis PLC, Novo Nordisk A/S, NXP Semiconductor NV and Wynn Resorts Ltd. have all reached their 52 week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 519.70
ACT's P/E(ttm) is ranked higher than
62% of the 838 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.00 vs. ACT: 519.70 )
ACT' s 10-Year P/E(ttm) Range
Min: 11.01   Max: 525.79
Current: 519.7

11.01
525.79
P/B 4.38
ACT's P/B is ranked higher than
66% of the 838 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. ACT: 4.38 )
ACT' s 10-Year P/B Range
Min: 1.08   Max: 5.9
Current: 4.38

1.08
5.9
P/S 3.96
ACT's P/S is ranked higher than
70% of the 838 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.73 vs. ACT: 3.96 )
ACT' s 10-Year P/S Range
Min: 0.99   Max: 4.01
Current: 3.96

0.99
4.01
PFCF 26.79
ACT's PFCF is ranked higher than
92% of the 838 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ACT: 26.79 )
ACT' s 10-Year PFCF Range
Min: 6.64   Max: 119.1
Current: 26.79

6.64
119.1
EV-to-EBIT 141.63
ACT's EV-to-EBIT is ranked higher than
65% of the 838 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. ACT: 141.63 )
ACT' s 10-Year EV-to-EBIT Range
Min: -262.1   Max: 145.1
Current: 141.63

-262.1
145.1
PEG 287.50
ACT's PEG is ranked higher than
79% of the 838 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ACT: 287.50 )
ACT' s 10-Year PEG Range
Min: 4.27   Max: 92.1
Current: 287.5

4.27
92.1
Shiller P/E 445.45
ACT's Shiller P/E is ranked higher than
72% of the 838 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 95.10 vs. ACT: 445.45 )
ACT' s 10-Year Shiller P/E Range
Min: 15.1   Max: 447.4
Current: 445.45

15.1
447.4
Current Ratio 1.98
ACT's Current Ratio is ranked higher than
66% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. ACT: 1.98 )
ACT' s 10-Year Current Ratio Range
Min: 1.31   Max: 9.8
Current: 1.98

1.31
9.8
Quick Ratio 1.59
ACT's Quick Ratio is ranked higher than
70% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. ACT: 1.59 )
ACT' s 10-Year Quick Ratio Range
Min: 0.78   Max: 8.82
Current: 1.59

0.78
8.82

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.51
ACT's Price/DCF (Projected) is ranked higher than
85% of the 838 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. ACT: 2.51 )
ACT' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 3.29
Current: 2.51

0.59
3.29
Price/Median PS Value 2.16
ACT's Price/Median PS Value is ranked higher than
58% of the 838 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. ACT: 2.16 )
ACT' s 10-Year Price/Median PS Value Range
Min: 0.67   Max: 5.39
Current: 2.16

0.67
5.39
Price/Peter Lynch Fair Value 79.74
ACT's Price/Peter Lynch Fair Value is ranked higher than
84% of the 838 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. ACT: 79.74 )
ACT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.52   Max: 73.2
Current: 79.74

0.52
73.2
Earnings Yield (Greenblatt) 0.70
ACT's Earnings Yield (Greenblatt) is ranked higher than
63% of the 794 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. ACT: 0.70 )
ACT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.7   Max: 11.4
Current: 0.7

0.7
11.4
Forward Rate of Return (Yacktman) 7.78
ACT's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.19 vs. ACT: 7.78 )
ACT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.4   Max: 16.2
Current: 7.78

-4.4
16.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:A60.Germany
Actavis, Inc. was is incorporated in 1985. The company's initial public offering was in February 1993. It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. On October 31, 2012, Watson Pharmaceuticals, Inc. completed the acquisition of the company's Group. Watson Pharmaceuticals, Inc. common stock was traded on the New York Stock Exchange under the symbol WPI until close of trading on January 23, 2013, at which time Watson Pharmaceuticals, Inc. changed its corporate name to Actavis, Inc. and changed its ticker symbol to ACT. The Company develops and out-license generic pharmaceutical products primarily in Europe through its Medis third-party business. Following the renaming, the Company also changed the name of its three reporting segments. The Global Generics segment has become Actavis Pharma, Global Brands has become Actavis Specialty Brands, and Distribution has become Anda Distribution. The Actavis Pharma segment includes off-patent pharmaceutical products that are therapeutically equivalent to proprietary products. The Actavis Specialty Brands segment includes patent-protected products and certain trademarked off-patent products that the Company sells and markets as brand pharmaceutical products. The Anda Distribution segment mainly distributes generic pharmaceutical products manufactured by third parties, as well as by the Company, primarily to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices. The Anda Distribution segment operating results exclude sales by Anda of products developed, acquired, or licensed by the Company's Actavis Pharma and Actavis Specialty Brands segments. The Actavis Pharma segment develops, manufactures, markets, sells and distributes generic, branded generic and OTC products. The Actavis Specialty Brands segment includes key promoted products such as Rapaflo, Gelnique, Crinone, Trelstar, GeneressTM Fe, Androderm, and Kadian and a number of non-promoted products. All pharmaceutical manufacturers, including the Company, are subject to extensive, complex and evolving regulation by the federal government, principally the FDA, and to a lesser extent, by the U.S. Drug Enforcement Administration Occupational Safety and Health Administration and state government agencies, as well as by various regulatory agencies in foreign countries where its products or product candidates are being manufactured and/or marketed. The Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other federal statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale and distribution of its products.
» More Articles for NYSE:ACT

Headlines

Articles On GuruFocus.com
Bernard Horn Comments on Actavis PLC Oct 30 2014 
The Top Net Buys Of The Hedge Fund Gurus Sep 12 2014 
Diamond Hill Capital Comments on Actavis PLC Jul 25 2014 
George Soros Reveals His Largest Stake Jul 23 2014 
Diamond Hill Capital Comments on Actavis Inc Jun 26 2014 
Diamond Hill Small Cap Fund Commentary – First Quarter 2014 Jun 25 2014 
Oakmark Funds' Bill Nygren Buys 4 New Stocks May 29 2014 
Top 5 Hedge Fund Net Buys May 21 2014 
Dodge & Cox First Quarter 2014 Commentary May 06 2014 
Should You Buy Actavis? Mar 18 2014 


More From Other Websites
Abbott Labs Pays $250 Million for Topera in Heart Health Move Oct 30 2014
The Zacks Analyst Blog Highlights: AbbVie, Mylan, Abbott Laboratories, Actavis and Mallinckrodt Oct 29 2014
Lannett Co. Gets Growth Rx In Generic Drugs Group Oct 27 2014
Video: Allergan Lifts Views; Valeant Suggests Higher Bid Oct 27 2014
Actavis CEO Saunders Has $70 Billion in Deals to Choose From Oct 23 2014
With Actavis Stake, Glenview Is Latest Firm to Enter Tangled Pharma Web Oct 23 2014
Glenview’s Robbins Recommends Actavis on Possible Deals Oct 23 2014
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent Oct 23 2014
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent Oct 23 2014
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin Oct 22 2014
Illumina Breaks Out Of Double-Bottom Base Oct 22 2014
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin Oct 22 2014
Actavis, Sanofi among bidders for Omega Pharma- Bloomberg Oct 20 2014
Actavis, Sanofi among bidders for Omega Pharma - Bloomberg Oct 20 2014
Actavis Said to Compete With Sanofi for Omega Pharma Deal Oct 20 2014
Noven Pharmaceuticals, Inc. press release :Noven files patent infringement lawsuit against Actavis Oct 19 2014
Akorn Finds Institutional Support In Base Oct 17 2014
Ironwood/Actavis Move Linzess into Phase II Study for OIC Oct 17 2014
Why Magnetar Capital initiates new position in Actavis Oct 17 2014
Will Actavis Win Competition For Allergan's Affection? Oct 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK